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Background: High density lipoprotein (HDL) cholesterol has a strong inverse relationship to cardiovascular disease. Despite significant increase of 
HDL with the cholesterol esther transfer protein (CETP) inhibitor torcetrapib, the use of torcetrapib was associated with an increased rate of major 
cardiovascular events and mortality in the ILLUMINATE trial.
We used a rat animal model that does not express CETP in order to assess the hypothesis that torcetrapib directly induces endothelial dysfunction 
and to reveal other torcetrapib-related off-target effects in a lipid independent study.
Methods: Endothelial function was analysed in isolated aortic rings from 16-20 weeks old spontaneously hypertensive rats (SHR) and Wistar-Kyoto 
rats (WKY), both treated with torcetrapib (100mg/kg/day) or placebo for three weeks. Blood pressure was measured before and during treatment.
Results: Blood pressure was transiently increased during the first 3 days of torcetrapib administration in SHR (P<0.05) and returned to baseline 
over the next days despite continued drug administration. No blood pressure effect was observed in torcetrapib-treated WKY rats.
Acetylcholine-induced endothelium dependent vasorelaxation in aortic rings from torcetrapib-treated SHR was impaired compared to placebo-
treated animals (P<0.05). No difference was observed in WKY.
We have identified a significant down-regulation of eNOS in torcetrapib-treated SHR as compared to placebo SHR, by both RT-PCR (-43.9%) and 
Western-blot analysis
(-45.7%), P=0.0080 and P=0.0498, respectively.
The contractile response to endothelin-1 was increased in aortic rings from torcetrapib-treated SHR vs. placebo SHR (P<0.01) which was not 
detected in WKY rats.
Additionally, torcetrapib-treated SHR showed a 30.3% higher aortic ET-1 level than placebo SHR as measured by RIA, P=0.0135.
A significant increase of aldosterone level was detected in plasma of SHR-T as compared to SHR placebo (+32.92%), P=0.0172
Conclusions: Our study demonstrates that torcetrapib induced endothelial dysfunction in SHR. Underlying mechanisms include decreased eNOS 
expression and activation of the endothelin system.
